SAB Biotherapeutics To Present At The 61st Annual Meeting Of The European Association For The Study Of Diabetes (Easd) Being Held September 15 – 19, 2025 At The Viecon - Vienna Congress & Convention Center In Vienna, Austria
Benzinga Newsdesk 1 year ago
BiotechNewsGeneral
MIAMI, Sept. 03, 2025 (GLOBE NEWSWIRE) -- SAB Biotherapeutics, Inc. (Nasdaq: SABS), ("SAB BIO" or the "Company"), a clinical-stage biopharmaceutical company with a novel immunotherapy platform that is developing a
MIAMI, Sept. 03, 2025 (GLOBE NEWSWIRE) -- SAB Biotherapeutics, Inc. (Nasdaq: SABS), ("SAB BIO" or the "Company"), a clinical-stage biopharmaceutical company with a novel immunotherapy platform that is developing a multi-specific human anti-thymocyte immunoglobulin (hIgG) for delaying the onset and progression of autoimmune type 1 diabetes (T1D), today announced that it will present at the 61st Annual Meeting of the European Association for the Study of Diabetes (EASD) being held September 15 – 19, 2025 at the VIECON - Vienna Congress & Convention Center in Vienna, Austria. The Company will have four oral presentations, as well as an INNODIA-hosted symposium at EASD.